These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39343612)

  • 1. Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series.
    Kawase S; Sakurai M; Masuda K; Kubota Y; Shindo T; Inokuchi A; Hayashi H; Nakayasu M; Shiozawa Y; Hirai T; Inoue T; Fujii T; Kim H; Koda Y; Kato J; Kataoka K
    J Clin Exp Hematop; 2024; 64(3):261-267. PubMed ID: 39343612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformed follicular lymphoma with laryngeal edema requiring tracheal intubation after tisagenlecleucel treatment: A case report.
    Shimazu R; Nakamura N; Goto T; Kaneda Y; Ikoma Y; Matsumoto T; Nakamura H; Kanemura N; Shimizu M
    Medicine (Baltimore); 2024 Sep; 103(36):e39630. PubMed ID: 39252248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
    Chen HH; Kuo CY; Ho CL; Chen YC
    Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
    Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
    Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma.
    Nakanishi Y; Marumo Y; Ri M; Kinoshita S; Suzuki T; Narita T; Kusumoto S; Komatsu H; Iida S
    Int J Hematol; 2023 Nov; 118(5):647-651. PubMed ID: 37436678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Inoue Y; Fujino T; Chinen S; Niiyama-Uchibori Y; Ide D; Kawata M; Hashimoto K; Takimoto-Shimomura T; Nakayama A; Tsukamoto T; Mizutani S; Shimura Y; Hirano S; Kuroda J
    Cureus; 2023 May; 15(5):e38905. PubMed ID: 37303362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W
    Cancer; 2024 Aug; 130(15):2660-2669. PubMed ID: 38578977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
    Sun Z; Xie C; Liu H; Yuan X
    Front Immunol; 2022; 13():778192. PubMed ID: 35154102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia.
    Shima H; Kurosawa T; Oikawa H; Kobayashi H; Nishi E; Yamazaki F; Tomita K; Shimada H
    Case Rep Oncol; 2022; 15(1):257-262. PubMed ID: 35431861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Gardner RA; Ceppi F; Rivers J; Annesley C; Summers C; Taraseviciute A; Gust J; Leger KJ; Tarlock K; Cooper TM; Finney OC; Brakke H; Li DH; Park JR; Jensen MC
    Blood; 2019 Dec; 134(24):2149-2158. PubMed ID: 31697826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.
    Ma Y; Zhou H; Zhang J; Zhang Q; Li Y; Xie R; Zhang B; Shen Z; Li P; Liang A; Zhou K; Han L; Hu Y; Xu K; Sang W; Wang X
    Front Immunol; 2024; 15():1448709. PubMed ID: 39399502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
    Kadauke S; Myers RM; Li Y; Aplenc R; Baniewicz D; Barrett DM; Barz Leahy A; Callahan C; Dolan JG; Fitzgerald JC; Gladney W; Lacey SF; Liu H; Maude SL; McGuire R; Motley LS; Teachey DT; Wertheim GB; Wray L; DiNofia AM; Grupp SA
    J Clin Oncol; 2021 Mar; 39(8):920-930. PubMed ID: 33417474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
    Sesques P; Kirkwood AA; Kwon M; Rejeski K; Jain MD; Di Blasi R; Brisou G; Gros FX; le Bras F; Bories P; Choquet S; Rubio MT; Iacoboni G; O'Reilly M; Casasnovas RO; Bay JO; Mohty M; Joris M; Abraham J; Castilla Llorente C; Loschi M; Carras S; Chauchet A; La Rochelle LD; Hermine O; Guidez S; Cony-Makhoul P; Fogarty P; Le Gouill S; Morschhauser F; Gastinne T; Cartron G; Subklewe M; Locke FL; Sanderson R; Barba P; Houot R; Bachy E
    J Hematol Oncol; 2024 Aug; 17(1):61. PubMed ID: 39107847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
    Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
    Front Immunol; 2021; 12():707191. PubMed ID: 34349766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.